Original language | English |
---|---|
Pages (from-to) | 597-599 |
Number of pages | 3 |
Journal | Psychiatry and Clinical Neurosciences |
Volume | 73 |
Issue number | 9 |
DOIs | |
Publication status | Published - 2019 Sept 1 |
ASJC Scopus subject areas
- Neuroscience(all)
- Neurology
- Clinical Neurology
- Psychiatry and Mental health
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Midlife cancer/diabetes and risk of dementia and mild cognitive impairment : A population-based prospective cohort study in Japan. / For the Japan Public Health Center-based Prospective Study Group.
In: Psychiatry and Clinical Neurosciences, Vol. 73, No. 9, 01.09.2019, p. 597-599.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Midlife cancer/diabetes and risk of dementia and mild cognitive impairment
T2 - A population-based prospective cohort study in Japan
AU - For the Japan Public Health Center-based Prospective Study Group
AU - Sadahiro, Ryoichi
AU - Sawada, Norie
AU - Matsuoka, Yutaka J.
AU - Mimura, Masaru
AU - Nozaki, Shoko
AU - Shikimoto, Ryo
AU - Goto, Atsushi
AU - Tsugane, Shoichiro
N1 - Funding Information: R.S. has received grants from the SGH Foundation and Novartis Pharma. Y.J.M. has received speaker’s honoraria from Morinaga Milk, Eli Lilly, and NTT Data and donations from Morinaga Milk within the past 3 years and is conducting collaborative research with Morinaga Milk. M.M. has received grants and/or speaker’s honoraria from Asahi Kasei Pharma, Astellas Pharmaceutical, Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Kracie, Meiji-Seika Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Yakuhin, Tanabe Mitsubishi Pharma, and Yoshitomi Yakuhin within the last 3 years. The remaining authors declare no conflicts of interest. Funding Information: This work was supported by the National Cancer Center Research and Development Fund. The present work was also supported by the Practical Research for Innovative Cancer Control project (No. 18ck0106370h0002) from the Japan Agency for Medical Research and Development and Foundation for Promotion of Cancer Research in Japan. These funding sources had no role in any aspect of study design, data collection and management, data analysis and interpretation, or manuscript submission. We appreciate the great efforts of all staff members in the Saku area who assisted in conducting this survey. We particularly thank Yukiko Miyasaka and Shogo Hotta who contributed the management of mental health screening.
PY - 2019/9/1
Y1 - 2019/9/1
UR - http://www.scopus.com/inward/record.url?scp=85068915442&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068915442&partnerID=8YFLogxK
U2 - 10.1111/pcn.12905
DO - 10.1111/pcn.12905
M3 - Letter
C2 - 31226234
AN - SCOPUS:85068915442
SN - 1323-1316
VL - 73
SP - 597
EP - 599
JO - Psychiatry and Clinical Neurosciences
JF - Psychiatry and Clinical Neurosciences
IS - 9
ER -